Earnings calendar/NEUP
Neuphoria Therapeutics Inc. (NEUP)
Quarter-by-quarter results read from the company's own filed statements — period end, filing date, diluted EPS, revenue and year-over-year change. Consensus estimates are shown only where one exists.
Latest filed quarter
The most recent quarter Neuphoria Therapeutics Inc. has filed, from EvidInvest's standardized statements.
Period end
Mar 31, 2026
Q3 FY2026
EPS (diluted)
$-0.09
Est. $-0.56 · +83.9%
Revenue
$0
As filed
Net income
$-505,063
As filed
EPS YoY
-101.4%
vs quarter ended 2025-03-31
Revenue YoY
-100.0%
vs quarter ended 2025-03-31
Next report
Oct 5, 2026
Scheduled · est. EPS $-1.58
Run-rate
Trailing twelve months, summed from the last four filed quarters.
TTM EPS (diluted)
$-9.64
2025-06-30 through 2026-03-31
TTM revenue
$-13,267
2025-06-30 through 2026-03-31
Filed quarters
11
On record here
EPS at or above estimate (4Q)
25%
Of the last four quarters that carry an estimate
Filed quarters
One row per filed statement, newest first
| Period end | Filed | EPS diluted | Revenue | EPS YoY | Revenue YoY | Est. EPS | Surprise |
|---|---|---|---|---|---|---|---|
| 2026-03-31Q3 FY2026 | 2026-05-15 | $-0.09 | $0 | -101.4% | -100.0% | $-0.56 | +83.9% |
| 2025-12-31Q2 FY2026 | 2026-02-17 | $-0.77 | $0 | +57.0% | -100.0% | $-0.61 | -26.2% |
| 2025-09-30Q1 FY2026 | 2025-11-14 | $-4.41 | $0 | -611.3% | -100.0% | $-1.33 | -232.4% |
| 2025-06-30Q4 FY2025 | 2025-09-29 | $-4.37 | $-13,267 | +58.3% | — | $-0.56 | -680.4% |
| 2025-03-31Q3 FY2025 | 2025-05-20 | $6.55 | $15.0M | +331.4% | — | $-0.47 | +1493.6% |
| 2024-12-31Q2 FY2025 | 2025-02-14 | $-1.79 | $662,715 | +66.3% | — | $-0.47 | -280.9% |
| 2024-09-30Q1 FY2025 | 2024-11-14 | $-0.62 | $10.1M | — | — | $-11.38 | +94.6% |
| 2024-06-30Q4 FY2024 | 2024-09-30 | $-10.48 | — | — | — | — | — |
| 2024-03-31Q3 FY2024 | 2025-05-20 | $-2.83 | $0 | — | — | — | — |
| 2023-12-31Q2 FY2024 | 2025-02-14 | $-5.31 | $0 | — | — | — | — |
| 2023-09-30Q1 FY2024 | 2024-11-14 | $0.00 | $0 | — | — | $-13.44 | +100.0% |